ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals to Present at Upcoming Investor Conferences

ANI Pharmaceuticals to Present at Upcoming Investor Conferences

PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will present at the following investor conferences:

  • Raymond James & Associates’ 47th Annual Institutional Investors Conference on Tuesday, March 3, 2026, at 7:30am ET



  • Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026, at 3:00pm ET



  • Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026, at 3:00pm ET



The live and archived webcasts will be accessible from the Company’s website at , under the Investors section under Events and Presentations. The replays of the webcasts will be accessible for 90 days.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit .

Investor Relations:

Courtney Mogerley, Argot Partners

T: 646-368-8014

E:



EN
24/02/2026

Underlying

ANIPANI Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ANI Pharmaceuticals Inc.

 PRESS RELEASE
Free
ANIP ANI Pharmaceuti...

ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 F...

ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectivelyTotal Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectively Quarterly and full year Purified Cortrophin® Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectivelyQuarterly and full year ILUVIEN® and YUTIQ® net revenue...

February 27, 2026 1 EN
 PRESS RELEASE
Free
ANIP ANI Pharmaceuti...

ANI Pharmaceuticals to Present at Upcoming Investor Conferences

ANI Pharmaceuticals to Present at Upcoming Investor Conferences PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will present at the following investor conferences: Raymond James & Associates’ 47th Annual Institutional Investors Conference on Tuesday, March 3, 2026, at 7:30am ETLeerink Partners Global Healthcare Conference on Tuesday, March 10, 2026, at 3:00pm ETBarclays 28th Annual Globa...

February 24, 2026 1 EN
Free Trial
ANIP ANI Pharmaceuti...

ANI Pharmaceuticals Inc: 2 directors

Two Directors at ANI Pharmaceuticals Inc sold 9,137 shares at between 77.739USD and 78.020USD. The significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...

ANIP ANI PHARMACEUTICALS INC.
02/24/26 February 24, 2026 1 EN
 PRESS RELEASE
Free
ANIP ANI Pharmaceuti...

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Finan...

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a conference call to ...

February 13, 2026 1 EN
 PRESS RELEASE
Free
ANIP ANI Pharmaceuti...

ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 20...

ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 to $7.64, respectivelyRare Disease business delivered exceptional growth with full year 2025 Purified Cortrophin® Gel net revenues of $347.8 million, up 76% year-over-year, and ILUVIEN and YUTIQ net revenues of $74.9 million, based on preliminary, una...

January 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch